

## Notice under Section 34A of the Medicines Act 1981 authorising off-label administration of COVID-19 Vaccine Nuvaxovid

Pursuant to section 34A of the Medicines Act 1981, I, Dr Ashley Bloomfield, Director-General of Health, make this Notice.


A dose of Novavax COVID-19 vaccine Nuvaxovid may be administered as a fourth dose after a primary course and first booster dose of a COVID-19 vaccine to which the Minister has given consent or provisional (a COVID-19 vaccine) to –

- a) any person aged 50 years and over;
- b) residents of aged care and disability care facilities, aged 18 years and over;
- c) severely immunocompromised people who received a three-dose primary course and a fourth dose as a first booster (noting this would be a fifth dose for these people), aged 18 years and over;
- d) people aged 18 years and over who have a medical condition that increases the risk of severe breakthrough COVID-19 illness;
- e) disabled people aged 18 years and over with significant or complex health needs or multiple comorbidities which increases the risk of poor outcomes from COVID-19;
- f) healthcare workers, including disability workers and aged care workers, aged 30 years and over–

at an interval of not less than six months since their last dose of a COVID-19 vaccine

The notice “Notice under Section 34A of the Medicines Act 1981 authorising off-label administration of COVID-19 Vaccine Nuvaxovid” made on 12 July 2022 is revoked.

Dated this 13<sup>th</sup> day of July 2022.



DR ASHLEY BLOOMFIELD, Director-General of Health.